# DAT-1604

Source: https://onco.cc/drugs/dat-1604/  
OnCo record `dat-1604` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DAT-1604 is an experimental small molecule from Danatlas Pharmaceuticals, in phase 1 trials for advanced solid tumours.

## Summary

DAT-1604 is a small molecule (oral tablet) from Danatlas Pharmaceuticals. A selective oral small-molecule inhibitor of DNA polymerase theta (Pol θ). Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06998173 not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DAT-1604
- Modality: Small molecule (oral tablet)
- Mechanism: A selective oral small-molecule inhibitor of DNA polymerase theta (Pol θ).

## Sources

- Danatlas Pharmaceuticals: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06998173
- ClinicalTrials.gov: trials of DAT-1604: https://clinicaltrials.gov/search?intr=DAT-1604

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [POLQ](https://onco.cc/targets/polq/)
- companies: [Danatlas Pharmaceuticals](https://onco.cc/companies/danatlas-pharmaceuticals/)
- trials: [Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor](https://onco.cc/trials/nct06998173/)

---
JSON: https://onco.cc/api/v1/entities/dat-1604.json